chr1-200111336-C-CAA
Position:
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 0P and 10B. BP6_ModerateBA1
The NM_205860.3(NR5A2):c.1230+29_1230+30dup variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0833 in 1,383,324 control chromosomes in the GnomAD database, including 1,856 homozygotes. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.13 ( 1138 hom., cov: 27)
Exomes 𝑓: 0.079 ( 718 hom. )
Consequence
NR5A2
NM_205860.3 intron
NM_205860.3 intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.881
Genes affected
NR5A2 (HGNC:7984): (nuclear receptor subfamily 5 group A member 2) The protein encoded by this gene is a DNA-binding zinc finger transcription factor and is a member of the fushi tarazu factor-1 subfamily of orphan nuclear receptors. The encoded protein is involved in the expression of genes for hepatitis B virus and cholesterol biosynthesis, and may be an important regulator of embryonic development. [provided by RefSeq, Jun 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -10 ACMG points.
BP6
Variant 1-200111336-C-CAA is Benign according to our data. Variant chr1-200111336-C-CAA is described in ClinVar as [Benign]. Clinvar id is 403261.Status of the report is criteria_provided_single_submitter, 1 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.148 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NR5A2 | NM_205860.3 | c.1230+29_1230+30dup | intron_variant | ENST00000367362.8 | NP_995582.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NR5A2 | ENST00000367362.8 | c.1230+29_1230+30dup | intron_variant | 1 | NM_205860.3 | ENSP00000356331 | A1 | |||
NR5A2 | ENST00000236914.7 | c.1092+29_1092+30dup | intron_variant | 1 | ENSP00000236914 | A1 | ||||
NR5A2 | ENST00000544748.5 | c.1014+29_1014+30dup | intron_variant | 2 | ENSP00000439116 | P4 |
Frequencies
GnomAD3 genomes AF: 0.129 AC: 16297AN: 126258Hom.: 1136 Cov.: 27
GnomAD3 genomes
AF:
AC:
16297
AN:
126258
Hom.:
Cov.:
27
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0480 AC: 4906AN: 102246Hom.: 397 AF XY: 0.0441 AC XY: 2426AN XY: 54958
GnomAD3 exomes
AF:
AC:
4906
AN:
102246
Hom.:
AF XY:
AC XY:
2426
AN XY:
54958
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0787 AC: 98940AN: 1257050Hom.: 718 Cov.: 0 AF XY: 0.0763 AC XY: 47498AN XY: 622444
GnomAD4 exome
AF:
AC:
98940
AN:
1257050
Hom.:
Cov.:
0
AF XY:
AC XY:
47498
AN XY:
622444
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.129 AC: 16299AN: 126274Hom.: 1138 Cov.: 27 AF XY: 0.124 AC XY: 7494AN XY: 60674
GnomAD4 genome
AF:
AC:
16299
AN:
126274
Hom.:
Cov.:
27
AF XY:
AC XY:
7494
AN XY:
60674
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 29, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency, outside ROI - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at